伊丽莎白Spurgeon % 0期刊文章% %一个玛丽Rensel贾斯汀Abbatemarco % % T的严重军团菌肺炎的阿仑单抗浸出第二个疗程后复发汇款多发性硬化症(P5.352) % D J神经病学2018% % P P5.352 % V 90% N 15补充% X目的:展示的军团菌肺炎与阿仑单抗治疗后。首页背景:阿仑单抗是一种anti-CD52单克隆抗体已被批准用于治疗复发汇款多发性硬化症(名RRMS)。T细胞和B细胞的损耗使呼吸道感染常见的不良事件,和更严重的肺部感染最近被描述。有只有一个军团菌肺炎病例报告和阿仑单抗治疗后。我们提出一个案件的军团菌肺炎第二次阿仑单抗的注入。设计/方法:一名35岁男子与名RRMS以前对待Copaxone(四年),Tecfidera(6个月),最终转变为疾病进展阿仑单抗。在他的第二届注入阿仑单抗,他发展了严重的胸痛和气短。他最终承认,转到ICU紧急插管ARDS。胸部CT显示弥漫性结节性和似的质量整顿。检查显示一个积极的军团菌尿抗原和文化从broncheoalveolar灌洗。他是用阿奇霉素治疗左氧氟沙星紧随其后。 He showed clinical improvement and was discharged to complete 21 days of levofloxacin. Repeat chest CT one month after discharged showed persistence of nodular and mass-like consolidations but with interval improvement.Results: N/AConclusions: Alemtuzumab is a highly effective yet potent treatment for RRMS. We report only the second case of Legionella pneumonia, occurring the last day of infusion (second course). The first case report of Legionella pneumonia occurred five days after infusion (first course). Other case reports of severe pulmonary infections have occurred days to weeks after the end of an infusion cycle. Due to the consistent timing of these rare infections, practitioners may want to reinforce best practices to prevent infections during this time period. This further highlights the need to diligently prevent and monitor this population for severe respiratory infections.Disclosure: Dr. Spurgeon has nothing to disclose. Dr. Abbatemarco has nothing to disclose. Dr. Rensel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Mary Rensel serves as a consultant or speaker for Biogen, Teva, Genzyme and Novartis. Dr. Rensel has received research support from Medimmune. %U

map